company background image
BGBI

BerGenBio OB:BGBIO Stock Report

Last Price

kr16.63

Market Cap

kr1.5b

7D

8.6%

1Y

-31.1%

Updated

22 May, 2022

Data

Company Financials +
BGBIO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BGBIO Stock Overview

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases.

BerGenBio Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for BerGenBio
Historical stock prices
Current Share Pricekr16.63
52 Week Highkr27.92
52 Week Lowkr13.79
Beta1.58
1 Month Change-13.02%
3 Month Change1.65%
1 Year Change-31.05%
3 Year Change-26.42%
5 Year Change-26.09%
Change since IPO-33.48%

Recent News & Updates

Feb 17
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

BGBIONO BiotechsNO Market
7D8.6%7.7%2.1%
1Y-31.1%-47.8%12.3%

Return vs Industry: BGBIO exceeded the Norwegian Biotechs industry which returned -47.8% over the past year.

Return vs Market: BGBIO underperformed the Norwegian Market which returned 12.3% over the past year.

Price Volatility

Is BGBIO's price volatile compared to industry and market?
BGBIO volatility
BGBIO Average Weekly Movement7.5%
Biotechs Industry Average Movement8.3%
Market Average Movement7.5%
10% most volatile stocks in NO Market13.0%
10% least volatile stocks in NO Market4.3%

Stable Share Price: BGBIO is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: BGBIO's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200742Martin Olinhttps://www.bergenbio.com

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19.

BerGenBio Fundamentals Summary

How do BerGenBio's earnings and revenue compare to its market cap?
BGBIO fundamental statistics
Market Capkr1.47b
Earnings (TTM)-kr309.36m
Revenue (TTM)kr774.00k

1,907x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BGBIO income statement (TTM)
Revenuekr774.00k
Cost of Revenuekr0
Gross Profitkr774.00k
Other Expenseskr310.14m
Earnings-kr309.36m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 24, 2022

Earnings per share (EPS)-3.49
Gross Margin100.00%
Net Profit Margin-39,969.51%
Debt/Equity Ratio0%

How did BGBIO perform over the long term?

See historical performance and comparison

Valuation

Is BerGenBio undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


3.84x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BGBIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BGBIO's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: BGBIO is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: BGBIO is unprofitable, so we can't compare its PE Ratio to the Norwegian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BGBIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BGBIO is good value based on its PB Ratio (3.8x) compared to the NO Biotechs industry average (4x).


Future Growth

How is BerGenBio forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


40.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BGBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BGBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BGBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BGBIO's revenue (43.7% per year) is forecast to grow faster than the Norwegian market (1% per year).

High Growth Revenue: BGBIO's revenue (43.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BGBIO is forecast to be unprofitable in 3 years.


Past Performance

How has BerGenBio performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-15.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BGBIO is currently unprofitable.

Growing Profit Margin: BGBIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BGBIO is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.

Accelerating Growth: Unable to compare BGBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BGBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: BGBIO has a negative Return on Equity (-80.47%), as it is currently unprofitable.


Financial Health

How is BerGenBio's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BGBIO's short term assets (NOK449.0M) exceed its short term liabilities (NOK64.9M).

Long Term Liabilities: BGBIO's short term assets (NOK449.0M) exceed its long term liabilities (NOK942.0K).


Debt to Equity History and Analysis

Debt Level: BGBIO is debt free.

Reducing Debt: BGBIO had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BGBIO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BGBIO has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 16.6% each year.


Dividend

What is BerGenBio current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BGBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BGBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BGBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BGBIO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BGBIO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Martin Olin (52 yo)

0.67

Tenure

kr3,898,000

Compensation

Mr. Martin Olin serves as Chief Executive Officer at BerGenBio ASA since September 8, 2021. Mr. Olin has been Chairman of the Board at AcouSort AB (publ) since April 28, 2021. He has experience from execut...


CEO Compensation Analysis

Compensation vs Market: Martin's total compensation ($USD399.09K) is about average for companies of similar size in the Norwegian market ($USD497.55K).

Compensation vs Earnings: Insufficient data to compare Martin's compensation with company performance.


Leadership Team

Experienced Management: BGBIO's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

Experienced Board: BGBIO's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BerGenBio ASA's employee growth, exchange listings and data sources


Key Information

  • Name: BerGenBio ASA
  • Ticker: BGBIO
  • Exchange: OB
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr1.474b
  • Shares outstanding: 88.66m
  • Website: https://www.bergenbio.com

Number of Employees


Location

  • BerGenBio ASA
  • Jonas Lies vei 91
  • Bergen
  • Hordaland
  • 5009
  • Norway

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/22 00:00
End of Day Share Price2022/05/20 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.